Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average
After reaching an important support level, Arcutis Biotherapeutics, Inc. (ARQT) could be a good stock pick from a technical perspective. ARQT surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 26.53%: Here's is How to Trade
The consensus price target hints at a 26.5% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcutis Biotherapeutics, Inc. (ARQT) Hits Fresh High: Is There Still Room to Run?
Arcutis Biotherapeutics (ARQT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Makes Arcutis Biotherapeutics (ARQT) a New Strong Buy Stock
Arcutis Biotherapeutics (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Arcutis' Q3 Earnings: Increased Foam Share, Better GTN, And Clear 2026 Guide Made Share Rally
Arcutis Biotherapeutics delivered strong Q3 results, driven by Zoryve foam's rapid adoption and a shift toward more patent-protected revenue. ARQT achieved earlier-than-expected profitability, established 2026 sales guidance of $455–$470M, and continues expanding Zoryve's label for broader indications. My DCF remodel values ARQT near $25/share, with a reasonable trading range of $15–$39, reflecting ambitious growth and margin assumptions.
Arcutis Biotherapeutics, Inc. (ARQT) Analyst/Investor Day Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Analyst/Investor Day October 28, 2025 10:30 AM EDT Company Participants Brian Schoelkopf Todd Watanabe - President, CEO & Director Todd Edwards Latha Vairavan - Chief Financial Officer Patrick Burnett - Executive VP & Chief Medical Officer Conference Call Participants Douglas DiRuggiero Presentation Operator Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics 2025 Third Quarter Financial Results and Investor Day Presentation.
Arcutis Biotherapeutics: Soaring On Q3 Earnings - Further Upside Likely (Upgrade)
Arcutis Biotherapeutics, Inc. surges after Q3 earnings, driven by strong Zoryve sales and outperformance versus Wall Street expectations. ARQT reported $99.2M in Q3 revenue (up 122% YoY), achieved profitability, and projects 2026 revenues of $455M-$470M with cash flow breakeven. Zoryve's expanding indications, large addressable market, and robust prescription growth support a bullish long-term outlook despite competition and reliance on a single product.
Arcutis Biotherapeutics, Inc. (ARQT) Q3 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago.
Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Todd Watanabe - President, CEO & Director Latha Vairavan - Chief Financial Officer Conference Call Participants Jason Jun Presentation Jason Jun Great. Well, thanks, everyone, for joining the fireside session today with the Arcutis team.
3 Biotech Catalysts Present Major Opportunity
For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.
Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate
Upgrading ARQT to buy due to explosive revenue growth, improving margins, and strong ZORYVE market adoption across multiple indications. ZORYVE now commands ~41% of non-steroidal topical psoriasis prescriptions, benefiting from dermatologist preference for steroid-sparing options and favorable insurance coverage. Key risks include fierce competition, potential generic entry, and single-asset dependency, but IP protections remain robust for now.
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
